Brokers Offer Predictions for INKT Q3 Earnings

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for shares of MiNK Therapeutics in a research report issued to clients and investors on Wednesday, November 4th. HC Wainwright analyst M. Keller anticipates that the company will earn ($0.67) per share for the quarter. HC Wainwright has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.48) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.71) EPS and FY2026 earnings at ($2.58) EPS.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.02).

A number of other brokerages also recently commented on INKT. Zacks Research downgraded MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. Finally, B. Riley Financial reaffirmed a “buy” rating and issued a $50.00 target price (up from $43.00) on shares of MiNK Therapeutics in a research report on Wednesday, October 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, MiNK Therapeutics presently has an average rating of “Hold” and a consensus price target of $44.00.

MiNK Therapeutics Stock Performance

NASDAQ INKT opened at $9.94 on Friday. The firm has a 50-day simple moving average of $11.26 and a 200 day simple moving average of $11.27. MiNK Therapeutics has a twelve month low of $8.48 and a twelve month high of $16.93. The stock has a market cap of $50.72 million, a PE ratio of -4.14 and a beta of 0.49.

Insider Buying and Selling at MiNK Therapeutics

In other news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer directly owned 74,195 shares of the company’s stock, valued at approximately $783,499.20. This represents a 8.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 20.40% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses.

MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.